Aldevron Announces Strategic Partnership with Acuitas Therapeutics
2024年5月14日 - 1:24AM
ビジネスワイヤ(英語)
Collaboration expands Aldevron’s
capabilities in mRNA lipid nanoparticle encapsulation
Aldevron, a leading global manufacturer of DNA, RNA, and
proteins used in cell and gene therapies and vaccine development,
today announced it has entered a strategic partnership with Acuitas
Therapeutics, Inc., a private biotechnology company specializing in
the development of delivery systems for nucleic acid therapeutics
based on lipid nanoparticles (LNPs). This partnership will allow
Aldevron to expand its capabilities in mRNA LNP encapsulation by
incorporating Acuitas’ proprietary LNP encapsulation platform,
increasing Aldevron’s services and capabilities as an mRNA
sequence-to-vial custom manufacturer.
In May of 2023, Aldevron announced the expansion of its mRNA
production capabilities to include Cytiva’s mRNA LNP encapsulation
and aseptic fill-finish platform. This new strategic partnership
with Acuitas Therapeutics, working with its encapsulation platform,
equips Aldevron with a diverse range of mRNA LNP technologies,
significantly enhancing its mRNA end-to-end drug product service
capabilities. The partnership will enable Aldevron to support
Acuitas’ LNP formulations and licensees.
“This collaboration with Acuitas is an exciting addition to our
existing mRNA sequence-to-vial services and will enable Acuitas
partners to leverage Aldevron’s extensive mRNA manufacturing
experience and comprehensive end-to-end capabilities,” said Mark
Wetzel, Vice President mRNA CDMO at Aldevron. “We look forward to
our continued partnership that is poised to enhance the landscape
of mRNA-based therapies, bringing faster timelines and hope, to
patients worldwide.”
“We have long known of Aldevron’s reputation and broad
experience in the manufacturing of nucleic acids and their
commitment to quality,” said Chris Barbosa, Vice President of
Technology Development at Acuitas Therapeutics, Inc. “We are
pleased to work with Aldevron to provide Acuitas partners with an
integrated path to clinical drug products using Acuitas’ lipid
nanoparticle manufacturing processes.” He added, “We look forward
to Aldevron’s contribution to working with us to support our global
partners in bringing new mRNA-based therapies to patients as
quickly and efficiently as possible.”
“The Acuitas technology, combined with Aldevron’s extensive
experience providing cutting-edge solutions for advancing therapies
and rigorous quality processes, provides an exceptional advantage,”
continued Wetzel. “With our two decades of experience in mRNA
technologies, Aldevron has developed a seamless workflow from mRNA
sequence-to-vial, and this partnership provides clients LNP
platform flexibility for the appropriate development stage for
their program.”
About Aldevron
Aldevron is a premier manufacturing partner, producing
high-quality plasmid DNA, mRNA, proteins, and other key components
for the development of vaccines, gene and cell therapies,
immunotherapies, and molecular diagnostics. Headquartered in Fargo,
North Dakota, with additional locations in Madison, Wisconsin, and
Lincoln, Nebraska, Aldevron supports scientists who are developing
revolutionary, lifesaving treatments for millions of people. To
learn more about how Aldevron is advancing biological science,
visit https://www.aldevron.com.
About Acuitas
Vancouver-based Acuitas Therapeutics (www.acuitastx.com)
partners with pharmaceutical and biotechnology companies, as well
as non-governmental organizations and academic institutes, to
advance nucleic acid therapeutics into clinical development and
commercialization. Acuitas’ lipid nanoparticle (LNP) technology is
clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO®
for the treatment of people with a rare genetic and otherwise fatal
disorder known as transthyretin amyloidosis and the Pfizer-BioNTech
COVID-19 vaccine, COMIRNATY®, which has protected billions of
people in more than 180 countries. Acuitas has also helped to
enable the first human proof-of-concept for genome base editing to
treat a serious genetic disease. The company is currently focused
on further innovations to its LNP carriers to advance the
development of novel gene therapies, such as epigenetic medicines,
to modulate gene expression without genetic editing to treat a
range of diseases, including cancer. In addition, Acuitas works
with partners on the development of improved vaccines – such as
multi-valent vaccines to prevent a range of infectious diseases
(including malaria, HIV/AIDS and tuberculosis) – and on novel
therapeutic vaccines against cancer, including personalized cancer
vaccines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513273856/en/
Alderon Contact: Ellen Shafer Senior Director of
Communications ellen.shafer@aldevron.com 701-551-8704
Acuitas Contact: Ruth Atherley Communications
ratherley@acuitastx.com 604-787-7379